Ozette in the news.

Read all about what we’ve been up to in our latest news and recent publications.

PSBJ Recognizes Ozette CEO Ali Ansary as 2023 40 Under 40 Honoree

May 16, 2023

The Puget Sound Business Journal honored Ozette CEO Ali Ansary on its list of the top 40 dynamic leaders under the age of 40 in the business community who are moving the needle for the PNW startup ecosystem by making an impact in business, philanthropy, and their communities. Ali’s leadership and conviction inspire our team every day to remember Ozette’s ultimate goal: To accelerate scientific discovery for new therapies that improve patients’ quality of life and cure disease.

Click through to PSBJ to read the full profile on Ali and Ozette, available with subscription.

Meet Team Ozette at CYTO 2023 | May 20-24

May 16, 2023

As the premiere cytometry conference convenes in Montréal this May at CYTO 2023, join our team for the first public look at how our single-cell infrastructure platform unlocks the full potential of modern, high-dimensional flow cytometry.

Four scientific presentations will highlight the speed, resolution, and scale of Ozette’s core technologies. You can also meet the team members who developed Ozette’s assay-to-insights solutions on the exhibition floor (booth 539) and hear directly from translational science and computational domain experts Cherie Green and Greg Finak in a commercial tutorial for a peek behind the scenes of our new product offerings.

Ozette welcomes Dr. Ashley Wilson to lead State-of-the-Art Immunology Lab.

April 7, 2023

We are thrilled to welcome Ashley Wilson, PhD, who will lend her deep expertise in immunology, cell therapy, and clinical trials to help drive the next generation of high-dimensional single cell immune assays. She and her team will employ Ozette’s state-of-the-art immunology lab to accelerate and power an “assay to analysis” solution that allows Ozette and partners to realize the full potential of every immune dataset.

“I’m excited to build value through collaboration and drive rapid new breakthroughs for our industry partners, harnessing Ozette’s exciting advancements that allow us to see single-cell immune data at a new remarkable resolution and breadth within days or weeks, not months or years.” said Dr. Wilson.

Immuno-oncology Pioneer Dr. Stanley Riddell Joins Ozette’s Board of Directors

January, 2023

We are honored to welcome world-renowned physician scientist and immuno-oncology pioneer Dr. Stanley Riddell to our Board of Directors. Dr. Riddell was the founding scientific director of the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Center and leads an innovative translational research program that has led to the first adoption of immunotherapies. He co-founded transformative biopharmaceutical companies including Juno Therapeutics (acquired by Celgene in 2018) and Lyell Immunopharma (IPO 2021).

“Ozette eliminates bottlenecks in immunotherapy research and development, accelerating the newest generation of therapies that harness the power of the immune system to treat disease. The computational and machine learning methods being developed at Ozette unlock insights across oncology, autoimmune disorders, and infectious diseases that cannot be otherwise surfaced using traditional approaches,” said Dr. Riddell. “I’m thrilled to join the Ozette team on their board as they pioneer and transform a space that is ripe for innovations.”

Ozette’s Corrie Ortega featured on Women Who Lead Biotech Panel.

December 19, 2022

Puget Sound Business Journal convened top executives in biotech to discuss the Pacific Northwest life sciences landscape, from the latest science in the pipeline, to growth strategies for the next generation of women in leadership. Leaders from Just-Evotec Biologics, Phase Genomics, SEngine Precision Medicine, and Ozette’s very own VP of Operations and Product, Corrie Ortega, shared their career insights gained along their journey from the bench to the boardroom.

BioTech Breakthrough Recognizes Ozette as the 2022 Overall Immunology Company of the Year

November, 2022

We’re honored to be named the 2022 Overall Immunology Company of the Year by BioTech Breakthrough. Ozette’s computational immune profiling tech breaks through complex, highly dimensional datasets to revolutionize our understanding of the human immune system. BioTech Breakthrough recognizes Ozette for accelerating scientific collaboration with automated and interpretable single-cell analysis at unprecedented speed, dimensionality, and annotation depth to capture the full value of single-cell immune data.

Ozette named one of the 21 most promising healthtech startups of 2022.

July 19, 2022

Business Insider features Ozette as one of the 21 most promising healthtech startups, along with Solv, Truepill and WELL Health, as ranked by VCs. Haomiao Huang at Kleiner Perkins nominated Ozette, noting that, “Ozette’s AI-driven solution has been succeeding in turning these high-dimensional problems in immune profiling into solvable and usable building blocks for drug development and scientific research.” Click through to Business Insider to read the full list, available with subscription.

Ozette announces $26MM in series A Funding

July 28, 2022

Ozette, a technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, today announced its $26MM Series A funding, led by Madrona Ventures. Other participating investors include Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners and Duke University.

CZI announces project with Ozette Co-Founder

July 19, 2022

We’re proud to announce Ozette co-founder and Scientific Advisor Dr. Raphael Gotardo’s role as principal investigator for The Chan Zuckerberg Initiative project to decode single-cell CITE-seq data, co-led by associate professor at the Fred Hutchinson Cancer Center Dr. Evan Newell. 

AI for immune data

August 18, 2021

Hear Ozette co-founder and CTO Greg Finak discuss how we leverage machine learning in next generation high-resolution immune profiling.

Ozette raises 6M seed

February 16, 2021

Fred Hutch spin out Ozette, raises 6M in seed funding to develop its AI powered immune monitoring platform in a round led by Madrona Venture Group. Ozette’s raise will fund team growth and technology development.

Case-studies & more

An incomplete list of Ozette news and featured publications.

Case Study

Going beneath the
surface of skin cancer.

We investigated our AI’s ability to predict treatment response to PD1 inhibiting immunotherapy in Merkel cell carcinoma and melanoma. We benchmarked our algorithmic approach against conventional analysis.

Case Study

Ozette’s AI in the battle
against COVID-19.

In-depth immune profiling reveals a T regulatory signature that correlates with COVID-19 disease severity, an important finding as Treg cells are potential targets for treatment strategies and fighting severe disease.

Case Study

Ozette’s AI aids advancement of cancer drug development.

Ozette’s technology, in conjunction with other new methods, reveal a distinct T cell population that suppresses immune effectiveness in the tumor microenvironment and helps inform drug development in immuno-oncology.

Ozette partners with Fred Hutch's CITN

Feb 14, 2022

Fred Hutch’s Cancer Immunotherapy Trials Network (CITN) has pioneered cancer immunotherapy trials which leverage immune profiling. In a unique collaboration, the CITN has tapped Ozette to analyze data from completed and ongoing early-phase clinical trials to provide unique insights on novel leads.